Concurrently, there is a marked increase in CD4/CD8+ T cell infiltration and IFN‐γ expression within the tumor tissue, ultimately enhancing the therapeutic efficacy of PD‐1 antibodies by boosting T cell immunity and improving the TME [153]. The gene discussed is CD8A; the disease is neoplasm.